Create Account | Sign In: Author or Forum

Search Symptoms

Category: Infections | Nursing | Pharmacy | Pulmonology | Critical Care | Emergency Medicine | Journal

Back to Journal Articles

Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19

Last Updated: May 11, 2020.

For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2, according to a study published online May 8 in The Lancet.

MONDAY, May 11, 2020 (HealthDay News) -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2, according to a study published online May 8 in The Lancet.

Ivan Fan-Ngai Hung, M.D., from Queen Mary Hospital in Hong Kong, and colleagues conducted a multicenter, randomized phase 2 trial involving 127 adults with COVID-19 admitted to six hospitals in Hong Kong. Patients were randomly assigned to a 14-day combination of lopinavir and ritonavir, ribavirin, and three doses of interferon beta-1b on alternate days (86 patients, combination group) or 14 days of lopinavir and ritonavir (41 patients, control group).

There was a median of five days from symptom onset to start of study treatment. The researchers found that compared with the control group, the combination group had a significantly shorter median time from start of study treatment to a negative nasopharyngeal swab (seven versus 12 days; hazard ratio, 4.37). Adverse events included self-limited nausea and diarrhea, which did not differ between the groups.

"Triple antiviral therapy with interferon beta-1b, lopinavir-ritonavir, and ribavirin [was] safe and superior to lopinavir-ritonavir alone in shortening virus shedding, alleviating symptoms, and facilitating discharge of patients with mild-to-moderate COVID-19," the authors write.

Abstract/Full Text
Editorial


Previous: ACR Issues Statement on Return of Routine Radiology Services Next: Bone Health Declining in U.S. Adults With and Without Prediabetes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: